MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the year ending 2025-12-31, CRSP had $49,302K increase in cash & cash equivalents over the period. -$345,928K in free cash flow.

Cash Flow Overview

Change in Cash
$49,302K
Free Cash flow
-$345,928K

Unit: Thousand (K) dollars (except for numbers of shares and EPS)
Cash Flow
2025-12-31
Net loss
-581,599
Depreciation and amortization
19,479
Stock-based compensation expense
72,499
Other non-cash items, net
23,528
Acquired in-process research and development
96,253
Accounts receivable
-25,000
Prepaid expenses and other assets
-3,337
Accounts payable and accrued expenses
44,894
Deferred revenue
-397
Operating lease assets and liabilities
-5,210
Other liabilities, net
4,258
Net cash used in operating activities
-345,014
Purchase of property, plant and equipment
914
Purchase of in-process research and development
25,000
Investment in equity securities
9,700
Sale of equity securities
702
Purchases of marketable debt securities
1,008,170
Maturities of marketable debt securities
1,011,277
Net cash used in (provided by) investing activities
-31,805
Proceeds from issuance of common shares, net of issuance costs
398,090
Proceeds from exercise of options and espp contributions, net of issuance costs
27,936
Net cash provided by financing activities
426,026
Effect of exchange rate changes on cash
95
Increase (decrease) in cash
49,302
Cash and cash equivalents at beginning of period
309,776
Cash and cash equivalents at end of period
359,078
Unit: Thousand (K) dollars

Time Plot

Show the time plot by selecting a row from the table.

CRISPR Therapeutics AG (CRSP)

CRISPR Therapeutics AG (CRSP)